NCT07481526Recruiting
A Prospecitve Multicenter, Observational Registry Study
A Multicenter Real-World Registry of Characteristics, Treatment Strategies, and Clinical Outcomes in Chinese Adults With Chronic Kidney Disease
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 13 Feb 2026
- Start date
- 27 Feb 2026
- Primary completion date
- 30 Dec 2028
- Lead sponsor
- AstraZeneca
- Diseases
- Chronic kidney disease
- NCT number
- NCT07481526
What you commit to
- Study type: Observational
- Planned participants: 3000
- From 27 Feb 2026 to the primary completion date, 30 Dec 2028
- 57 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment.
Other illness
- Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months.
- Presenting with ESRD, RRT, acute kidney injury (AKI), acute kidney disease (i.e., kidney injury or a decline in renal function persisting for ≤3 months) as a primary disease condition at enrollment.
Age
- Having a life-threatening comorbidity with life expectancy \< 2 years.
Other
- Pregnant or breastfeeding women.
Who the study is looking for
- Male or female patients aged ≥18 years.
- Willing and able to provide written informed consent to participate in the study.
- Confirmed CKD diagnosis at enrolment, defined by at least one of the following:
- eGFR \<60 mL/min/1.73 m² for ≥3 months, OR
- Evidence of kidney damage (e.g., UACR ≥30 mg/g or UPCR ≥150 mg/g, structural abnormality on imaging, or kidney biopsy findings consistent with chronic kidney injury) persisting for ≥3 months
Sex: All · Does not accept healthy volunteers
Sites (57)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.